The article ‘Can super-antibody drugs be tamed?’ (Nature 440, 855–856; 2006) contained two errors. Steve Anderton researches autoimmune disease, not the use of antibodies to overcome cancer. And he did not state that the CD25 receptor may be a safer target for antibody therapies than CD28; instead, he suggested that CD25 may be of some use as a marker for regulatory T cells, and that other costimulatory molecules, such as CD154, may represent safer targets for immunomodulatory antibodies. Nature apologizes for any confusion.